Recent developments highlight INVO Fertility's financial results, service expansions, and patent achievements.

• INVO Fertility reported a net loss of $5 million in Q1 2026, with the stock declining following the announcement [N1].
• The company also reported a drop in Q1 loss, indicating some improvement in financial performance [N2].
• INVO Fertility shares surged after the issuance of a patent for a modified INVOcell device, reflecting investor interest in product innovation [N3].
• The company has expanded fertility services by introducing platelet-rich plasma therapy at the Wisconsin Fertility Institute [N7].
• Telehealth services have been expanded to enhance access to expert fertility care across multiple states [N8].
• INVO Fertility enhanced its fertility services with expanded training and improved pricing for the INVOcell device [N6].

The company has demonstrated growth in fertility services and revenue, supported by product innovation such as the patented modified INVOcell device. Expansion into telehealth and new therapies broadens its service reach. Leadership continuity and strategic focus on core fertility operations provide a foundation for operational execution.

The company faces challenges including multiple reverse stock splits, indicating potential capital structure and liquidity pressures. The current ratio below 1.0 and cash ratio of 0.3 suggest liquidity constraints. Reported net losses and fluctuations in quarterly results highlight ongoing profitability risks. Competition and regulatory changes in fertility services may also impact business stability.

INVO Fertility's moat is supported by its proprietary INVOcell device, for which it has received patent protection, and its expanding fertility service offerings including innovative therapies and telehealth access. The company's focus on training and pricing improvements for its device and services may contribute to competitive differentiation in the fertility services market.

• Liquidity Risk: The company's current ratio of 0.71 and cash ratio of 0.3 as of June 30, 2026, indicate that current liabilities exceed current assets, posing liquidity risk.
• Profitability Risk: INVO Fertility reported a net loss of $5 million in Q1 2026 and has experienced fluctuations in quarterly profitability, which may affect financial stability.
• Market and Regulatory Risks: The fertility services sector is subject to regulatory changes and competitive pressures that could impact the company's operations and growth prospects.
• Capital Structure Risk: The company has implemented multiple reverse stock splits, which may reflect challenges in maintaining share price and market capitalization.

• INVO Fertility, Inc. operates in the fertility services sector, providing fertility-related medical services and products.
• The company has expanded its fertility services including the introduction of platelet-rich plasma therapy at the Wisconsin Fertility Institute and expanded telehealth services to enhance access to expert fertility care in multiple states [N7][N8].
• INVO Fertility has enhanced its fertility services with expanded training and improved pricing for its INVOcell device [N6].
• The company reported record revenue growth in Q4 2024 and full year 2024 financial results [N9].
• INVO Fertility has implemented multiple reverse stock splits, including a 1-for-3 reverse stock split effective July 21, 2025, and announced plans for additional reverse stock splits [N5].
• The company’s leadership includes CEO Steven Shum (since 2019), CFO Terah Krigsvold (since December 2025), and Chief Business Officer Andrea Goren (since December 2025) [S1].
• INVO Fertility reported Q1 2025 financial results with a strategic focus on core fertility operations [N10].
• The company’s Q1 2026 results showed a net loss of $5 million [N1] and a reported drop in Q1 loss [N2].
• INVO Fertility shares surged following the issuance of a patent for a modified INVOcell device [N3].
• The company’s financial snapshot as of June 30, 2026, includes revenue of approximately $2.18 million, net income of $888,740, basic EPS of $0.42, diluted EPS of $0.35, cash and equivalents of about $1.96 million, current assets of $4.6 million, current liabilities of $6.52 million, a current ratio of 0.71, and a cash ratio of 0.3 [S2].
• The company is registered on Nasdaq under the ticker symbol IVF [S1].